TNFRSF4 and melanoma: Mice-bearing two tumors derived from B16F10 melanoma were used as a model to monitor the systemic antitumor benefits of the novel triple therapeutic strategy combining radiotherapy, CpG and anti-OX40 agonistic antibody (RT + CpG + αOX40) (Fig. 2A).